The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research Federal Grant Program (CFDA 93.837), awarded a $595,464 Project Grant to Cerulean Scientific Inc. on September 25, 2024. The funding supports the development and commercialization of Cerulean Scientific's tethered liquid perfluorocarbon (TLP) coating technology for peripheral vascular grafts (PVGs). The key objectives are to evaluate the durability, anti-fouling properties, and thrombogenicity of...
This STTR Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $294,063 to Biomembretics, Inc. to develop and demonstrate a high-volume manufacturing technology for microfluidic oxygenators for extracorporeal membrane oxygenation (ECMO) to treat respiratory failure. The project aims to advance a bioinspired microfluidic oxygenator technology that can safely and effectively oxygenate blood, addressing limitations of the...
This federal Project Grant award from the Department of Energy (DOE) Office of Science, provided under the Office of Science Financial Assistance Program (CFDA 81.049), awarded $200,000.00 to Advanced Cooling Technologies Inc. (ACT) to develop a low-cost, high-volume, and durable coating method for bipolar plates. The project aims to be completed by April 9, 2024. Additionally, ACT has subcontracted the University of South Carolina to provide characterization of the bipolar plate coating through...
This $6,059,162 Cooperative Agreement, awarded by the U.S. Department of Energy's Office of Energy Efficiency and Renewable Energy (CFDA 81.087 Renewable Energy Research and Development), aims to demonstrate PPG Industries Inc.'s platinum group metal-free coating process as a viable means of producing porous transport layer (PTL) materials with high electrical conductivity, high corrosion resistance, and significant stack cost reductions. The project focuses on developing scalable and economical...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research (CFDA 93.837) program provides $1,564,220.00 to The Trustees of the University of Pennsylvania to develop an imaging-compatible pre-clinical ex vivo lung perfusion (EVLP) system. The goal is to obtain structural, functional, and metabolic biomarkers that can be used to non-invasively assess donor lung health and optimize EVLP parameters for reconditioning lungs prior...
This National Science Foundation Project Grant of $100,000 supports research into polyelectrolyte multilayered surfaces for use in human mesenchymal stem/stromal cell manufacturing. The goal is to develop a scalable and controllable polymeric coating composed of natural polymers to improve the cell expansion process used in producing therapeutic human mesenchymal stromal cells. The coating is constructed via layer-by-layer assembly of collagen and heparin and has been shown to increase cell...
The National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH), awarded a $790,738 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Circulatech LLC, a for-profit limited liability company located in Pembroke Pines, FL. The purpose of this project is to develop and validate Circulatech's "ThoraFlush" device, a proactive chest tube designed to maintain patency and prevent clotting in over 455,000 annual...
This Cooperative Agreement award from the National Science Foundation will support Environmental Protective Coatings LLC's development of durable, omniphobic coatings through Scops Coating Technologies LLC. Funded under NSF's Technology, Innovation, and Partnerships program (CFDA 47.084), the $1,013,950 award aims to validate pilot-scale production and enhance weatherability of fluorine-free, self-cleaning coating materials. Key objectives include pilot-scale production to enable...
This Project Grant award from the National Science Foundation (CFDA 47.084 - NSF Technology, Innovation, and Partnerships program) provides $274,274 to X-Cor Therapeutics Inc., a minority-owned small disadvantaged business in Washington, DC, to develop a novel respiratory dialysis system for treating chronic obstructive pulmonary disease (COPD) patients. The project aims to optimize a prototype that can efficiently remove excess carbon dioxide from the blood of COPD patients, with the goal of...
Acatechol, Inc. was awarded a $274,982 National Science Foundation (NSF) Small Business Innovation Research (SBIR) Phase I grant to develop an innovative anti-infective coating for Foley catheters. The project aims to create a hybrid coating that combines biofilm-repellent and antimicrobial properties to provide prolonged resistance against pathogen colonization and catheter-associated urinary tract infections (CAUTIs). This work is being conducted under the NSF Technology, Innovation, and...